What are the clinically significant and FDA-approved monoclonal antibodies (monoclonal antibodies) and related drugs that are missing from the provided list?

Clinically Significant FDA-Approved Monoclonal Antibodies Missing from Your List

Complement System Inhibitors

You are missing eculizumab, the first FDA-approved C5 inhibitor, which preceded zilucoplan and remains widely used for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. 1

• Eculizumab targets C5 complement protein and was the pioneering therapy in this class before zilucoplan 1
• Ravulizumab is a long-acting C5 inhibitor that offers extended dosing intervals compared to eculizumab 1

CD38-Targeting Antibodies

Your list includes daratumumab but omits isatuximab, another FDA-approved anti-CD38 monoclonal antibody for multiple myeloma. 2

• Isatuximab-irfc is approved in combination with pomalidomide/dexamethasone or carfilzomib/dexamethasone for relapsed/refractory multiple myeloma 2

PD-1/PD-L1 Immune Checkpoint Inhibitors

You are missing cemiplimab, dostarlimab, and avelumab—all FDA-approved PD-1/PD-L1 inhibitors with distinct oncologic indications. 3

• Cemiplimab (anti-PD-1) is approved for cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer 3
• Dostarlimab (anti-PD-1) is approved for mismatch repair-deficient solid tumors and endometrial cancer 1
• Avelumab (anti-PD-L1) is approved for Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma 1

Bispecific T-Cell Engagers and Novel Formats

Your list lacks the recently approved bispecific antibodies that represent a major therapeutic advance, particularly in hematologic malignancies. 1

• Elranatamab-bcmm is a BCMA/CD3 bispecific T-cell engager for relapsed/refractory multiple myeloma after ≥4 prior therapies 1
• Talquetamab-tgvs targets GPRC5D/CD3 for relapsed/refractory multiple myeloma 1
• Teclistamab-cqyv is a BCMA/CD3 bispecific antibody for triple-class refractory multiple myeloma 1
• Blinatumomab (CD19/CD3 bispecific) is approved for B-cell acute lymphoblastic leukemia 4

CD20-Targeting Antibodies

You included rituximab, obinutuzumab, ofatumumab, and ocrelizumab but are missing ublituximab, a newer glycoengineered anti-CD20 antibody. 1, 5

• Ublituximab is FDA-approved for chronic lymphocytic leukemia and follicular lymphoma 1, 5

HER2-Targeting Antibodies and Conjugates

Your list includes trastuzumab and pertuzumab but omits margetuximab and the antibody-drug conjugates trastuzumab deruxtecan and trastuzumab emtansine. 1

• Margetuximab is an Fc-optimized anti-HER2 antibody for metastatic breast cancer 1
• Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate approved for HER2-positive and HER2-low breast cancer 1
• Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate for HER2-positive breast cancer 1

EGFR-Targeting Antibodies

You listed cetuximab but are missing panitumumab and necitumumab, both FDA-approved anti-EGFR antibodies. 1

• Panitumumab is a fully human anti-EGFR antibody for metastatic colorectal cancer 1
• Necitumumab is approved for squamous non-small cell lung cancer in combination with chemotherapy 1

CD30-Targeting Antibody-Drug Conjugate

Brentuximab vedotin is a critical antibody-drug conjugate missing from your list. 1

• Brentuximab vedotin targets CD30 and is approved for Hodgkin lymphoma and anaplastic large cell lymphoma 1

Clostridium difficile Toxin Neutralization

Bezlotoxumab is an FDA-approved monoclonal antibody for preventing recurrent C. difficile infection. 1

• Bezlotoxumab neutralizes C. difficile toxin B to reduce recurrence risk in patients receiving antimicrobial therapy for CDI 1

SLAMF7-Targeting Antibody

Elotuzumab, which you may have intended to include, targets SLAMF7 (not listed in your categories). 1

• Elotuzumab is an anti-SLAMF7 antibody approved for multiple myeloma in combination with lenalidomide/dexamethasone or pomalidomide/dexamethasone 1

GD2-Targeting Antibody

Dinutuximab is an anti-GD2 antibody approved for pediatric neuroblastoma. 4

• Dinutuximab targets the disialoganglioside GD2 on neuroblastoma cells 4

CCR4-Targeting Antibody

Mogamulizumab is an anti-CCR4 antibody approved for cutaneous T-cell lymphoma. 1

• Mogamulizumab targets CC chemokine receptor 4 on malignant T cells 1

Amyloid-Beta Targeting Antibodies

Aducanumab and lecanemab are FDA-approved anti-amyloid-beta antibodies for Alzheimer's disease. 6

• Aducanumab targets aggregated amyloid-beta in the brain 6
• Lecanemab is a humanized IgG1 antibody that binds amyloid-beta protofibrils 6

BCMA-Targeting Antibody-Drug Conjugate

Belantamab mafodotin is an anti-BCMA antibody-drug conjugate for multiple myeloma. 1

• Belantamab mafodotin delivers monomethyl auristatin F to BCMA-expressing myeloma cells 1